Budiodarone - Espero BioPharma
Alternative Names: ATI-2042Latest Information Update: 21 Oct 2024
At a glance
- Originator ARYx Therapeutics
- Developer Espero BioPharma
- Class Benzofurans; Class III antiarrhythmics; Small molecules
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atrial fibrillation
- Discontinued Ventricular tachycardia
Most Recent Events
- 21 Oct 2024 XYRA receives label guidance from the US FDA for managing Atrial fibrillation with budiodarone and wearable monitoring devices in phase III trial
- 27 Feb 2024 XYRA plans a phase III trial for Atrial fibrillation in 2024
- 26 Feb 2024 Xyra completes the End of phase II meeting with the US FDA